Abstract
Mast cells are increasingly recognized as critical players in elicitation and maintenance of different inflammatory related disorders, like allergy, autoimmne diseases and cancer. Mast cells maturate within the tissue and are able to adapt to microenvironmental changes. Together with the ability to produce multiple pro- and anti-inflammatory mediators upon activation, mast cells are highly capable of exerting immunomodulatory functions. Cross-linking of receptor bound IgE is the best known mechanism of antigen-specific mast cell activation. In this review we focus on a different route of activation, via immunoglobulin free light chains (FLCs). Here, we describe current knowledge and concepts on FLCs based on preclinical models and data on human subjects, after briefly recapitulating early research findings on FLCs. Furthermore, because FLC research mainly focuses on mast cells, several mast cell mediated pathologies and mouse models for mast cell research will be discussed. Whether targeting of mast cells is beneficial for the treatment of specific disorders has to be addressed in future studies. Specific inhibition of FLC-mediated mast cell activation may be an interesting avenue to treat chronic inflammatory diseases.
Keywords: Immunoglobulin free light chain, T cell factor, mast cells, inflammation, allergy, contact sensitivity, delayed type hypersensitivity
Current Pharmaceutical Design
Title:Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Volume: 18 Issue: 16
Author(s): Tom Groot Kormelink, Philip W. Askenase and Frank A. Redegeld
Affiliation:
Keywords: Immunoglobulin free light chain, T cell factor, mast cells, inflammation, allergy, contact sensitivity, delayed type hypersensitivity
Abstract: Mast cells are increasingly recognized as critical players in elicitation and maintenance of different inflammatory related disorders, like allergy, autoimmne diseases and cancer. Mast cells maturate within the tissue and are able to adapt to microenvironmental changes. Together with the ability to produce multiple pro- and anti-inflammatory mediators upon activation, mast cells are highly capable of exerting immunomodulatory functions. Cross-linking of receptor bound IgE is the best known mechanism of antigen-specific mast cell activation. In this review we focus on a different route of activation, via immunoglobulin free light chains (FLCs). Here, we describe current knowledge and concepts on FLCs based on preclinical models and data on human subjects, after briefly recapitulating early research findings on FLCs. Furthermore, because FLC research mainly focuses on mast cells, several mast cell mediated pathologies and mouse models for mast cell research will be discussed. Whether targeting of mast cells is beneficial for the treatment of specific disorders has to be addressed in future studies. Specific inhibition of FLC-mediated mast cell activation may be an interesting avenue to treat chronic inflammatory diseases.
Export Options
About this article
Cite this article as:
Groot Kormelink Tom, W. Askenase Philip and A. Redegeld Frank, Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases, Current Pharmaceutical Design 2012; 18 (16) . https://dx.doi.org/10.2174/138161212800166059
DOI https://dx.doi.org/10.2174/138161212800166059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polymer-based Drug Delivery Systems Applied to Insects Repellents Devices: A Review
Current Drug Delivery Improving Safety of Gene Therapy
Current Drug Safety The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Cytosolic Phospholipase A2 Inhibitors as Therapeutic Agents for Neural Cell Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Latent Viral Infections in Mechanically Ventilated Patients
Current Respiratory Medicine Reviews Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Combinatorial Approaches to Iminosugars as Glycosidase and Glycosyltransferase Inhibitors
Combinatorial Chemistry & High Throughput Screening Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Recombinant Rhabdoviruses as Potential Vaccines for HIV-1 and Other Diseases
Current HIV Research Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry From Alpha to Omega with Aβ: Targeting the Multiple Molecular Appearances of the Pathogenic Peptide in Alzheimers Disease
Current Medicinal Chemistry Natural Killer Cells Adjudicate Every Stage of Anti-Viral Immune Response
Current Immunology Reviews (Discontinued) Progressive Supranuclear Palsy: What Do We Know About it?
Current Medicinal Chemistry